OSE IMMUNOTHERAPEUTICS |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.6 EUR | -0.71% |
|
+12.00% | +30.84% |
| Apr. 17 | OSE: licensing agreement with AbbVie enters into force | CF |
| Apr. 17 | OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie | MT |
Chart calendar OSE Immunotherapeutics
000ba0635ba7.a6aulGmkuqJlCDCReCt6NuvM2VA_WSxZ-6dUcdBwn3Q.NMCd7TPV08AtPQf2QHguTpqVkDdOIGdvktYYCOYS9Tk9x9zfBvbw-yRmcQ~e7553bf77367eb9dcaa702a5a3edb66c
Upcoming events on OSE Immunotherapeutics
Past events on OSE Immunotherapeutics
| 2024-04-03 | Paris European Small & Midcap Event |
| 2024-03-27 01:00 pm | Q4 2023 Earnings Release |
| 2024-02-28 12:00 pm | OSE Immunotherapeutics SA and Abbvie Agreement Call |
| 2024-02-07 | European Midcap Event |
| 2024-01-29 | Invest Securities Biomed Forum |
| 2024-01-16 | Molecular and Cellular Biology Keystone Symposia |
| 2024-01-07 | JPMorgan Healthcare Conference |
| 2023-12-04 | Geneva Midcap Conference |
| 2023-11-13 | Protein & Antibody Engineering Europe Summit |
| 2023-10-31 | Society for Immunotherapy of Cancer Meeting |
| 2023-10-19 | European Society for Medical Oncology Congress - Abstract Number : #697P |
| 2023-10-10 | AACR-NCI-EORTC International Conference - Abstract No:35371 |
| 2023-09-27 12:00 am | Q2 2023 Earnings Release |
| 2023-09-21 | International Cancer Immunotherapy Conference - Poster Number: P269 |
| 2023-09-21 | International Cancer Immunotherapy Conference - Poster Number: P271 |
| 2023-09-20 | International Cancer Immunotherapy Conference - Poster Number: P270 |
| 2023-09-10 | H.C. Wainwright Global Investment Conference |
| 2023-07-19 09:30 am | Tumor Myeloid-directed Therapies Summit - Nicolas Poirier |
| 2023-06-27 09:00 am | Cytokine-Based Drug Development Summit - Nicolas Poirier |
| 2023-06-22 04:00 am | Shareholders Meeting |
Annual results
| Fiscal Period | December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
|
Net sales Million EUR | Released Forecast Spread | 24,5 16,9 44.97% | 26,0 19,7 31.56% | 10,4 13,7 -23.91% | 26,3 16,8 56.26% | 18,3 16,0 14.22% | 2,23 3,00 -25.77% |
|
EBITDA Million EUR | Released Forecast Spread | 4,96 2,90 71.14% | -1,15 -2,18 47.38% | -18,6 -5,03 -269% | -14,3 -15,8 9.81% | -15,6 -25,4 38.32% | -20,4 -29,8 31.58% |
|
EBIT Million EUR | Released Forecast Spread | 4,85 1,85 161.86% | -1,47 -2,26 34.86% | -19,0 -5,76 -229.6% | -16,6 -19,5 14.84% | -18,4 -27,3 32.7% | -23,0 -23,4 1.99% |
|
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | 4,71 1,85 154.37% | -1,46 -6,09 75.96% | -19,2 -13,7 -40.13% | -17,2 -19,8 12.91% | -18,0 -28,6 36.96% | -23,2 -26,2 11.37% |
|
Net income Million EUR | Released Forecast Spread | 5,49 3,40 61.47% | -4,65 -1,92 -142.72% | -16,6 -8,48 -95.18% | -16,9 -17,9 6.02% | -17,8 -26,0 31.81% | -23,0 -31,6 27.26% |
|
EPS EUR | Released Forecast Spread | 0,35 0,27 29.63% | -0,31 -0,13 -139.94% | -1,06 -0,54 -98.01% | -0,93 -0,98 4.62% | -0,96 -1,42 32.16% | -1,18 -1,67 29.34% |
| Announcement Date | 28/03/19 | 26/03/20 | 26/03/21 | 30/03/22 | 27/04/23 | 27/03/24 |
Quarterly results
| Fiscal Period | December | 2019 S1 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2023 S1 |
|---|---|---|---|---|---|---|---|
|
Net sales Million EUR | Released Forecast Spread | 16,0 19,0 -15.9% | 5,85 0,00 - | 4,58 0,00 - | 8,98 12,2 -26.43% | 17,3 7,24 139.25% | 1,36 |
|
EBIT Million EUR | Released Forecast Spread | -11,9 -11,2 -6.44% | -11,6 -2,63 -340.64% | -5,05 -11,6 56.41% | |||
|
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | -12,0 -11,2 -7.03% | -11,8 -2,63 -347.53% | -5,45 -11,6 52.97% | |||
|
Net income Million EUR | Released Forecast Spread | -13,4 -11,2 -19.51% | -11,5 2,47 -564.72% | -5,36 -11,6 53.75% | -11,9 | ||
|
EPS EUR | Released Forecast Spread | 0,03 0,65 -95.38% | -0,21 -0,58 63.79% | -0,85 -0,53 -60.38% | -0,64 0,15 -526.67% | -0,29 -0,57 49.12% | -0,64 |
| Announcement Date | 05/09/19 | 17/09/20 | 26/03/21 | 21/09/21 | 30/03/22 | 27/09/23 |
More events
Past sector events for OSE Immunotherapeutics
| Today | PHARMARON BEIJING CO., LTD.: Q1 2024 Earnings Release |
| Today | HANGZHOU TIGERMED CONSULTING CO., LTD: Q1 2024 Earnings Release |
| Today | PURETECH HEALTH PLC: Q4 2023 Earnings Release |
| 2024-04-24 04:15 pm | ICON PUBLIC LIMITED COMPANY: Q1 2024 Earnings Release |
| 2024-04-24 10:21 am | SYNGENE INTERNATIONAL LIMITED: Q4 2024 Earnings Release |
| 2024-04-24 07:06 am | CUREVAC N.V.: Q4 2023 Earnings Release |
| 2024-04-24 01:45 am | ADDLIFE AB: Q1 2024 Earnings Release |
| 2024-04-24 01:00 am | EVOTEC SE: Q4 2023 Earnings Release |
| 2024-04-23 | SINO BIOLOGICAL,INC.: Q4 2023 Earnings Release |
| 2024-04-23 | MORPHIC HOLDING, INC.: Q1 2024 Earnings Release (Projected) |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- OSE Stock
- Calendar OSE Immunotherapeutics
